Pharmaceutical

Novartis and PTC Therapeutics link to develop Huntington’s therapy

Novartis has entered a worldwide licence and partnership agreement with PTC Therapeutics for the development of PTC518.

Dec 3, 2024 - 06:00
Novartis and PTC Therapeutics link to develop Huntington’s therapy
Novartis has entered a worldwide licence and partnership agreement with PTC Therapeutics for the development of PTC518.
Read the original article

Tags:

Previous Article

J&J’s sBLAs seek FDA approval of TREMFYA for paediatric conditions

Next Article

Faron Pharma secures UK innovation passport for blood cancer immunotherapy

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

QBiotics wins FDA orphan status for rainforest-derived cancer drug

QBiotics wins FDA orphan status for rainforest-derived ...

Feb 16, 2024

The promising role of GLP-1RAs in NASH

The promising role of GLP-1RAs in NASH

Jun 29, 2023

Opinion: STAT readers on patient advocacy, the utility of diagnostic tests, and more

Opinion: STAT readers on patient advocacy, the utility ...

Dec 23, 2023